An updated review on gout
Keywords:
updated review, gout, staple cultureAbstract
First identified by the Egyptians in 2640 BC, podagra (acute gout occurring in the first metatarsophalangeal joint) was later recognized by Hippocrates in the fifth century BC, who referred to it as 'the unwalkable disease'. The term is derived from the Latin word gutta (or 'drop'), and referred to the prevailing medieval belief that an excess of one of the four 'humors' - which in equilibrium were thought to maintain health - would, under certain circumstances, 'drop' or flow into a joint, causing pain and inflammation. Throughout history, gout has been associated with rich foods and excessive alcohol consumption. Because it is clearly associated with a lifestyle that,atleast in the past, could only be afforded by the affluent, gout has been referred to as the 'disease of kings'. Although there is evidence that colchicine, an alkaloid derived from the autumn crocus (Colchicum autumnale), was used as a powerful purgative in ancient Greece more than 2000 years ago, its first use as a selective and specific treatment for gout is attributed to the Byzantine Christian physician Alexander of Tralles in the sixth century AD.
Downloads
References
Edward P. Hartung. "Symposium on Gout. Historical Considerations." Metabolism.
Schwartz S: Disease of distinction. [http://www. stephanaschwartz.com/PDF/disease_of_ distinction.pdf.]
Copeman WSC: A Short History of the Gout and the Rheumatic Diseases. Los Angeles, CA: University of California Press; 1964.
Zollner N: Influence of various purines on uric acid metabo- lism. Bibl Nutr Dieta 1973. 19:34-43.
Choi HK, Atkinson K, Karlson EW, Willett W, Curhan G: Purine- rich foods, dairy and protein intake, and the risk of gout in men. N Engl J Med 2004, 350:1093-1103.
William Stukeley. Of the gout, in two parts. First a letter to Sir Hans Sloan about the cure by oyls externally apply'd; secondly, a treatise on the cause and cure of the gout. London: Roberts; 1734; 1736, 2nd edition, p. 29.
Geoffrey Parker. Philip I: Library of the World Biography. (Hutchinson: London, 1978). pp. 191-2.
Schumacher HR Jr. Osteoarthritis and crystal deposition diseases. Curr Op Rheumatol 1998:10:244-5.
Saag KG, Choi H: Epidemiology, risk factors, and lifestyle modifications for gout. Arthritis Res Ther. 2006, 8: S2-10.1186/ar1907.
Simkin PA. Management of gout. Ann Intern Med 1979; 90: 812-6
Emmerson BT. The management of gout. N Engl J Med 1996; 334: 445-51.
Schumacher HR Jr. Crystal-induced arthritis: an overview. Am J Med 1996; 100 Supp1 A: 465-52S.
Perez-Ruiz F, Calabozo Raluy M, Alonso-Ruiz A. Treatment of chronic gout: a new approach to an ancient disease. Rev Esp Reumatol 1999; 26: 21-5
McCarty DJ: A historical note: Leeuwenhoek's description of crystals from a gouty tophus. Arthritis Rheum 1970, 13:414-418.
Garrod AB: The Nature and Treatment of Gout and Rheumatic Gout. London: Walton and Maberly; 1859.
McCarty DJ, Hollander JL: Identification of urate crystals in gouty synovial fluid. Ann Intern Med 1961, 54:452-460
McCarty DJ Jr, Kohn NN, Faires JS: The significance of calcium 923 phosphate crystals in the synovial fluid of arthritic patients: the 'pseudogout syndrome'.
Unger S, Tausche AK, Kopprasch S, Bornstein SR, Aringer M, Grässler J. Molecular basis of primary renal hyperuricemia: role of the human urate transporter hURAT1. Z Rheumatol.
Graessler J, Graessler A, Unger S, et al. Association of the human urate transporter 1 with reduced renal uric acid excretion and hyperuricemia in a German Caucasian population. Arthritis Rheum.
Wortmann RL. The management of gout: it should be crystal clear. J Rheumatol.
Choi HK, Mount DB, Reginato AM. American College of Physicians; American Physiological Society: Pathogenesis of gout. Ann Intern Med.
Tausche AK, Unger S, Richter K, et al. Hyperuricemia and gout: diagnosis and therapy. Internist (Berl) 2006;47:509-522. [PubMed]
Mikuls TR, Farrar JT, Bilker WB, Fernandes S, Schumacher HR, Jr, Saag KG. Gout epidemiology: results from the UK General Practice Research Database
Zhang W, Doherty M, Bardin T, et al. EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT) Ann Rheum Dis.
Published
How to Cite
Issue
Section
Copyright (c) 2022 International journal of health sciences
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Articles published in the International Journal of Health Sciences (IJHS) are available under Creative Commons Attribution Non-Commercial No Derivatives Licence (CC BY-NC-ND 4.0). Authors retain copyright in their work and grant IJHS right of first publication under CC BY-NC-ND 4.0. Users have the right to read, download, copy, distribute, print, search, or link to the full texts of articles in this journal, and to use them for any other lawful purpose.
Articles published in IJHS can be copied, communicated and shared in their published form for non-commercial purposes provided full attribution is given to the author and the journal. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
This copyright notice applies to articles published in IJHS volumes 4 onwards. Please read about the copyright notices for previous volumes under Journal History.
